NORFLEX
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Nov 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORFLEX is an oral extended-release tablet approved in 1959 with unknown mechanism of action and indication profile. The specific therapeutic class and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals declining team investment and potential workforce reductions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect mature product status with minimal hiring. Working on NORFLEX offers limited career growth opportunity; roles focus on maintaining market share and managing transition to generic competition.
Brand ManagerSales Representative
Worked on NORFLEX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.